全球化研究报告-PDF版

世界卫生组织（WHO）：2025呼吸道合胞病毒儿科药物优化会议报告（英文版）（32页）.pdf

Paediatric drug optimization for respiratory syncytial virus Meeting report,April 2025Paediatric dru.

2025-07-10 32页 5星级

IHE：2025年欧洲癌症比较报告：疾病负担、成本及药物与分子诊断可及性（英文版）（234页）.pdf

ihe.se Comparator Report on Cancer in Europe 2025-Disease Burden,Costs and Access to Medicines and .

2025-07-09 234页 5星级

欧洲制药工业协会联合会（EFPIA）：2025年欧洲制药行业关键数据报告（英文版）（28页）.pdf

www.efpia.euThe Pharmaceutical Industry in FiguresKey Data 2025EFPIA Key Data|20252Thanks to advance.

2025-07-09 28页 5星级

罗兰贝格：2050年全球趋势纲要报告之趋势六：健康与护理（2025年版）（英文版）（98页）.pdf

1Roland Berger|Megatrend 6Health&CareTrend Compendium 20502025 Edition2Roland Berger|The Roland Berg.

2025-07-09 98页 5星级

艾昆纬：重塑亚洲医疗格局：2025年行业五大风向研判报告（英文版）（22页）.pdf

White PaperPrevailing Winds:Five Forces Reshaping Asias Healthcare in 2025SAM SCIBETTA,Consultant,Consulting Services,IQVIADEVARAJ SUBRAMANIAM,Principal,Consulting Services,IQVIATable of contentsIntroduction 1Prevailing winds 2The silver surge 2Middle class expansion 2Geopolitical headwinds 3Technologys forward march 35 key healthcare themes 4Theme 1:From digital consumers to digital health societies 4Theme 2:From volume-to value-based care 6Theme 3:Private services accelerate 9Theme 4:Health sovereignty reigns nationalism meets necessity 11Theme 5:AI finds its footing and its edge in Asia 13Key implications for stakeholders 16Industry 16Healthcare services 16Government 16Conclusion 17References 18About the authors 19About IQVIA Asia Pacific 19 |1IntroductionAsias healthcare landscape in 2025 is undergoing a rapid transformation,shaped by deep-rooted demographic,economic,and technological shifts.As these“prevailing winds”converge,five foundational themes are emerging to redefine how health is accessed,financed,and delivered across this diverse region(Figure 1).Firstly,digital health societies are emerging as increasingly connected and health-conscious consumers embrace digital tools to manage their care.This shift is being enabled by governments investing in national health platforms,interoperable data systems,and frameworks that support digital integration.Secondly,healthcare systems are strategically transitioning from a volume-based approach to a value-driven model.This shift marks a new phase where patient outcomes,operational efficiency,and equity take precedence over the mere quantity of procedures performed.Thirdly,private healthcare services are rapidly advancing as the consolidation and expansion of hospitals and pharmacy chains become standard practice.Fourthly,health sovereignty is increasingly an imperative,and countries are beginning to prioritize domestic manufacturing,regulatory autonomy,and strategic control over supply chains and health infrastructure:a shift amplified by geopolitical uncertainty and lessons from the pandemic.Finally,Artificial Intelligence(AI)is set to find its footing in Asia,as consumers across the region are more open to its potential and uses.Figure 1:2025 APAC healthcare landscape Abbreviations:APAC Asia Pacific Source:IQVIA analysisDigital health societies emergeVolume to value in carePrivate services accelerateHealth sovereignty reignsAI finds its footing and its edge in AsiaTransformation of digital consumers and digital health products into integrated health ecosystemsRising costs and new technologies are leading to new initiatives to prioritize value in care across APACPrivate healthcare services take center stage in advancing delivery and filling gap of underserved populationCountries prioritize independence and moving up the value chain for healthcare production and servicesPilots turn into scaled solutions as policies and investment align to bridge care delivery gaps in APAC12345Silver surge Aged populations expand even in developing AsiaMiddle class expansion Growth in middle-class drives new health consumption patternsGeopolitical headwinds Global tensions lead to uncertainty in trade landscapeTechnological march New and more accessible technology emerges2|Prevailing Winds:Five Forces Reshaping Asias Healthcare in 2025Prevailing windsThe silver surgeAsia is experiencing one of the fastest demographic transitions in the world.By 2050,more than one in five people,or 20%of the population,across the Asia-Pacific region will be over 65 years of age,up from just 10%in 2020.While East Asia leads this trend,Southeast Asia and India are quickly catching up(Figure 2).This demographic shift is straining existing infrastructure and reshaping demand toward chronic disease management,eldercare,and home-based solutions.This shift is also prompting health systems to evaluate the best mechanisms to transition from acute,episodic models to proactive,forward-looking care frameworks to support sustainability and health outcomes.Figure 2:Elderly populations are burgeoning,driving up rates of chronic disease363#Ybgc %0 0Pp0902020205019504%515-6465 Total Pop.,Bn87%WyxW9$P%)of health expenditures are paid out of pocket Integrated economies of scale:As one of Indias largest hospital chains,Narayana is leveraging economies of scale,using assembly line concepts for surgery,reducing the average length of stay reengineering the design,materials,and use of medical equipment to reduce the cost of ownership Integrated responsibility:New HMO framework is designed so hospital group bears both upside potential and downside risk“VDO is a powerful tool that ensures clinical and patient outcomes can be delivered in a sustainably”Prof Yeoh,Chief Executive NUHS“I urge private health facilities to consider this.As a minister,I want value-based healthcare not pay-for-service but pay-for-outcome”Dzulkefy Ahmad,Health Minister,Malaysia“If you standardize everything,you can bring down the cost of healthcare dramatically”Dr.Shetty,Narayana Health FounderAbbreviations:VDO Value Driven Outcomes;NUHS National University Health System;VBC Value Based Care;HMO Health Management OrganizationSource:NUHS,IHH,Narayana Health,IQVIA analysis |9Theme 3:Private services accelerateFigure 9:The trend towards consolidation in Asia0 0Pp00,00020,00030,00040,00050,00060,00070,00080,00090,000GDP per capita-USD(2022)IndiaVietnamIndonesiaPhilippinesChinaThailandMalaysiaFranceAustraliaJapanSingaporeKoreaGermanyUSAThe private healthcare sector in Asia is undergoing a strategic evolution.What was once a story of geographic expansion and bed count growth is now leading to a phase of consolidation,integration,and vertical capability building in the private healthcare service sector.As public systems face fiscal and operational strain,private players are stepping in to fill the gap while simultaneously redefining the care experience.From hospital groups to pharmacy chains,the most successful private providers are eyeing a transformation toward full-service health platforms,delivering care across the continuum,and increasingly dominating the ecosystem in which they operate.As countries move up the income curve,healthcare markets tend to follow a familiar trajectory:from fragmented networks of independent,often physician-owned clinics and hospitals to consolidated corporate chains that offer scale,consistency,and brand trust(Figure 9).This shift is driven by both demand-side and supply-side forces.On the demand side,rising consumer expectations for standardization,digital access,and quality assurance push patients toward branded networks.On the supply side,regulatory pressure,workforce requirements,and capital intensity make it harder for standalone providers to compete.Larger chains benefit from economies of scale,shared technology platforms,centralized procurement,and cross-facility data integration.Across Asia,health systems are now experimenting with combinations of these models,adapting them to local financing structures,disease burden,and data capabilities(Figure 8).From pilot projects to population-wide shifts,countries are beginning to rewire their systems for value.The shift is opening space for a new class of health innovators:AI-powered remote monitoring,chronic care management,and digital health platforms that can enhance value in care models across the region.Modern trade(chained retailers)share as%of total retail salesSource:World Bank,IQVIA analysis10|Prevailing Winds:Five Forces Reshaping Asias Healthcare in 2025Figure 10:Formation of Asia Mega-Chains in private hospital sectorIn many middle-income markets in Southeast and South Asia,this consolidation wave is underway.Major hospital chains such as IHH Healthcare in Malaysia and Singapore,Bangkok Dusit Medical Services in Thailand,and Apollo in India are expanding into Tier 2 and 3 cities while integrating diagnostics,pharmacies,and insurance partnerships across their networks.Now,acquisitions and consolidations are occurring at a rapid pace,including both through private equity and domestic chain acquisitions(Figure 10).The result CVC acquires Siloam Hospital Group for$1.6B Columbia Asia and Ramsay Sime Darby$1.2B mergerManipals series of acquisition to$1BIndonesian property giant Lippo Karawaci Tbk has sold a majority stake in Siloam International Hospitals to CVC Capital Partners Modernization of Indonesias largest hospital chain:Active transformation and modernization of 41 hospitals and 30 clinics across 23 provinces in Indonesia Anticipated local expansion:In early 2025,Siloam expresses intent to acquire First Reits Indonesia hospital portfolio,comprising 11 hospitals,two integrated hospitals and malls,one integrated hospital International network integration:In 2022,CVC invested in Vietnams Phuong Chau Healthcare Group,then took a majority stake Philippines chain The Medical City as it expands its investment network regionallySiloam Hospital Group acquisition increases CVCs SEA operational beds by 3,800Asia OneHealthcare will operate 4200 beds in total,with 2900 across Malaysia aloneAcquisition makes Manipal Indias largest hospital chain with over 10,500 operating bedsSime Darby sells Asia healthcare JV stake to Columbia Asia and undergo rebranding as OneHealthcare Establishment of a new private hospital mega-chain:Asia OneHealthcare has expanded its 30 medical facilities across Malaysia,Vietnam and Indonesia to focus on further building mid-size hospitals in residential areas Continuous investment activity:Additional acquisition of five super-specialty hospitals in Malaysia from TE Asia Healthcare across Kuala Lumpur and Penang Large domestic M&A:Malaysia has overseen continuous acquisitions of hospitals,including IHHs$900m acquisition of Island Hospital PenangIndias Manipal Hospitals,acquired by Temasek in 2023,is now competing with Apollo for largest footprint in India Medica Synergie:In 2024,majority stake was acquired in the 1,200-bed Medica Synergie chain as it aims to expand its footprint in east India Previous expansions:Manipal previously acquired Emami Groups AMRI Hospitals in 2023(1,200 beds)and Columbia Asia India in 2021(11 hospitals and 1,300 beds)Competition for largest footprint heats up:Expects to treat 7 million patients annually,Manipal now boasts a network of 10,500,narrowly surpassing Apollo and its network of over 10,000 hospital beds across IndiaAbbreviations:AMRI Advanced Medical Research Institute Source:Siloam,Asia OneHealthcare,Manipal,Temasek,IQVIA analysis |11Figure 11:U.S.trade deficits with ASEAN have grown051015202530354045ChinaASEAN-6South KoreaTaiwanIndia20162023%of US trade deficit by country/region,2016 and 2023Abbreviations:ASEAN Association of Southeast Asia NationsSource:Nikko Asset Management,ITC,HSBC,IQVIA analysisis often a nation-spanning set of private hospital chains that continue to grow and dominate emerging markets.A similar phenomenon is taking place within pharmacy chains,with major chain businesses such as Generika in the Philippines and BIG Pharmacy in Malaysia undertaking major acquisitions to expand their footprint within each country(Link).Theme 4:Health sovereignty reigns nationalism meets necessityAs the global political situation enters a period of renewed volatility,health systems across Asia are recalibrating their dependencies.First,the emergence of geopolitical tensions in multiple global arenas and the growing uncertainty around the direction of U.S.foreign policy including the potential for an accelerating tariff war have cast a spotlight on the risks of global interdependence in healthcare(Figure 11).The COVID-19 pandemic revealed the fragility of cross-border supply chains,and todays geopolitical climate is reinforcing the need for strategic autonomy.For many countries in Asia,health sovereignty is no longer a policy ambition;rather,it is an operational necessity.The shift toward domestic self-sufficiency is already well underway.Across Asia,countries are moving to localize the production of critical inputs,from pharmaceuticals and biologics to medical devices,diagnostics,and healthcare services(Figure 12).India has launched extensive incentive schemes under its Production-Linked Incentive Program,covering APIs,vaccine production,and high-end MedTech.The country is investing in manufacturing clusters and encouraging global players to partner with local Contract Development and Manufacturing Organizations(CDMOs).Indonesia meanwhile has made health industrialization a policy priority,with a local content target.Meanwhile,Association of Southeast Asian Nations(ASEAN),more broadly,is pushing for further regional integration with the Pharmaceutical Regulatory Policy,which aims to harmonize standards and encourage intra-ASEAN trade and development of pharmaceutical products,which would reduce reliance on imports from outside the bloc.12|Prevailing Winds:Five Forces Reshaping Asias Healthcare in 2025Figure 12:Steps toward health sovereignty in APACChinas bolstering of local R&D for biotechnology sectorIndonesias Special Economic Zones(SEZs)for healthcareIndias domestic initiatives for pharmaceutical manufacturingChina has risen to be a dominant force in the industry,driven by its ability to innovate swiftly Faster ability to secure human subject data:China has been able to secure proof of concept subject data faster and more extensively than other countries,consistently ranked first in global clinical trial numbers Favored regulatory environment:NMPA established 4 accelerated pathways for drug approvals.In 2024 alone,NMPA approved 48 first-in-class innovative drugs,the highest number in the past five years Growing international standing:In 2022,Chinese pharmaceutical and biotechnology companies accounted for 12%of big pharmas introduction contracts.This number has risen to 29%and 31%in 2023 and 2024Chinas share of global biopharma companies increased from 5%to 16%from 2017 to 2024International Health Tourism SEZ in Batam aims to attract$440M in investments developing internationalstandard healthcare by 2026By 2027,the government aims to cut API imports by 75%to reduce risks associated with external supply disruptionsIn 2024,Indonesia launched 2 new SEZs focused on healthcare in Banten and Batam,with indication that more are on the way Focusing on international medical tourism:Batams proximity to Singapore and Malaysia creates an opportunity to appeal as destination for medical tourism Strengthening local medical tourism:2 million Indonesian currently seek treatment abroad the SEZ aims to redirect a portion of these patients back to Batam Advancing healthcare infrastructure:Business incentives facilitates collaboration and knowledge exchange with international players,including Indias Apollo Hospital,in addition to reducing treatment costsProduction linked incentive scheme aims to incentivize local pharmaceutical manufacturing Establishing greenfield manufacturing plants:Under PLI,35 new greenfield manufacturing facilities have been sanctioned across various states,including Gujarat,Maharashtra,Himachal etc.Reducing import dependence:As of March 2025,domestic production of 38 critical APIs has already begun,witnessing a 50%reduction in import dependence for several high-demand drug ingredients Attracting investments:$3billion designated by the government to attract investments into pharmaceuticals and medical devices,with$4 billion attracted as of April 2024 |13All of this is leading toward a world in which more pharmaceuticals,biologics,and devices are produced,regulated,and procured domestically.Multinational firms operating in Asia are already facing stronger expectations to manufacture in-market,co-invest with local partners,and comply with evolving domestic content requirements.While this may challenge traditional global sourcing models,it also creates opportunities:local CDMOs,regional Active Pharmaceutical Ingredient suppliers,and adaptive regulatory teams will become indispensable allies in navigating this new environment.Theme 5:AI finds its footing and its edge in AsiaAI has long since shifted from the experimental frontier to a mass market product.While early dominance of generative AI stemmed from large language models in the U.S.China is now rapidly catching up,particularly in foundation models and domain-specific applications.Meanwhile,the broader Asia-Pacific region is now outpacing the West in AI-related patents,with more than 80ing granted in the region(Figures 13 and 14).As we enter 2025,Asia is not just beginning to adopt AI;it is increasingly producing and refining it.Figure 13:China approaches parity with the U.S.in AIFigure 14:AI patents expand into Asia Pacific1,150Jan-24 Mar-24 May-24 Jul-24 Sep-24 Nov-24 Jan-251,2001,2501,3001,3501,40002010201520202023509%8QA%6b1%5%3%North AmericaAsia PacificROWEuropeBeyond technical capability,Asias edge lies in cultural and political openness to AI.Surveys consistently show that populations across Asia believe AI will profoundly change daily life and is likely to have more benefits than drawbacks(Figure 15).Countries in the region also score higher in terms of the level of excitement inspired by AI tools.This openness is being mirrored by governments,which are now launching regulatory sandboxes,AI strategies,and publicprivate pilots to fast-track adoption.LMSYS Chatbot Arena performance,country top model,Jan 24 Jan 25Granted AI patents(%of world total)by region,2010-23Abbreviations:AI Artificial Intelligence;LMSYS Large Model Systems OrganizationSource:Stanford University Artificial Intelligence Index Report 2025Abbreviations:AI Artificial Intelligence;ROW Rest of WorldSource:Stanford University Artificial Intelligence Index Report 202514|Prevailing Winds:Five Forces Reshaping Asias Healthcare in 2025Figure 15:AI is very positively perceived in AsiaProducts and services using AI58%will profoundly change my daily life in the next 3-5 years86exXY4%.make me excited80cvv8FbxHI9%have more benefits than drawbacksChinaIndonesiaThailandUnited KingdomGermanyUnited StatesIndia%respondents answering yesAbbreviations:AI Artificial IntelligenceSource:Stanford AI Index,IQVIA analysisEmpathyPatients confidence in careTop-3 Dx accuracyManagement planEscalation recommendationPerceived openness and honestyPCPAMIEPatient actor perspectiveSpecialist physician perspectiveAIs potential impact on healthcare,meanwhile,continues to grow.In the latest clinical study published in April 2025,Google DeepMinds Articulate Medical Intelligence Explorer(AMIE)was shown to outperform primary care physicians across multiple clinical reasoning metrics,demonstrating both diagnostic accuracy and empathetic communication(Figure 16).Figure 16:AI starts to outperform even in the human aspects of healthcarePerformance of Googles Articulate Medical Intelligence Explorer(AMIE)AI system compared to PCPs,April 2025Abbreviations:AMIE Articulate Medical Intelligence Explorer;AI Artificial Intelligence;PCPs Primary Care PhysiciansSource:Tu,T.,Schaekermann,M.,Palepu,A.et al.Towards conversational diagnostic artificial intelligence.Nature(2025)|15The technology has arrived.The ongoing challenge lies in identifying suitable models for deployment:facilitating support for overburdened clinicians,improving access in rural regions,and integrating intelligence into patient care pathways.Asia is particularly well positioned to lead this next phase.Its digital health infrastructure is rapidly maturing,its care systems are under pressure,and governments are increasingly willing to trial new models at scale.The opportunity in the region is to leapfrog legacy systems,enabling more,including health coverage and better outcomes.The opportunity is thus not just to catch up,but to leap ahead.16|Prevailing Winds:Five Forces Reshaping Asias Healthcare in 2025Key implications for stakeholdersThese five themes are shifting roles,responsibilities,and opportunities for stakeholders across the system.For industry players,healthcare service providers,and governments alike,adapting to this new landscape will require a nuanced understanding of the forces at play.Localization imperative:Tariffs,local trial mandates,and sovereignty-driven procurement are incentivizing localization of operations.Regional manufacturing hubs(e.g.,Indias Production Linked Incentives,Indonesias bio-localization policies)will reward early movers,while CDMOs should align to rapidly adapt to divergent national standards and ensure a competitive edge.Partnership-driven ecosystems flourish:The path to market now runs through local platforms.Pharma and MedTech companies should integrate into digital health ecosystems.It is anticipated that more collaborations will occur involving international industry leaders,local healthcare ecosystem participants,and AI providers in the upcoming years.The landscape will increasingly favor flexible firms that are open to building models that meet external requirements.Essential outcomes:As payers and providers increasingly demand real-world value demonstration,outcome tracking and risk-based pricing will define commercial success across markets.Industry players able to generate,analyze,and act on local outcomes data,particularly in chronic and specialty care,will lead the charge.Tech-enabled scale becomes a differentiator:Integration across Electronic Medical Records,diagnostic and service provision(including virtual care)is fast becoming a baseline.Chains that deploy unified data layers can more effectively move toward the type of predictive,preventive care that will define success and enable operational and clinical return on investment in the years to come.New care models=new value engines:In rising cost environments and with increasing government pressure,resilience for providers will come from reinventing care models.Expanding and sustaining margins will require a data-driven approach to evolving delivery and producing the value that is required,including for the bottom line of the business.Data governance must supplement health infrastructure:Robust data governance frameworks are urgent,especially as national health records,AI tools,and decentralized platforms create new privacy,security,and interoperability challenges.Balance financing reform with innovation:Universal health coverage schemes are already shifting focus from inclusion to long-term sustainability.To do this successfully will require successful expansion of risk pooling and digitization initiatives built upon the best economic and outcome data.IndustryHealthcare servicesGovernment |17ConclusionAs the healthcare landscape in Asia evolves,it is not just adapting to global healthcare trends it is beginning to reshape them.The convergence of demographics,economic growth,and digital acceleration has created a momentum shift.The eventual direction of this momentum shift will depend on the five foundational trends outlined in this white paper:digitized societies,value-based care,private sector transformation,national sovereignty,and AI-led innovations.These are not passive forces,but more of an invitation to lead.Governments,industry stakeholders,and providers across the region should integrate into emerging ecosystems to serve as foundational elements for resilient,inclusive,and intelligent healthcare systems.Those who participate now decisively,locally,and collaboratively will influence future developments.18|Prevailing Winds:Five Forces Reshaping Asias Healthcare in 2025References1.Artificial Intelligence Index Report 2025.Stanford University,2025.2.Digital Nations in Asia Pacific.GSMA,Sept.2024, Middle Class:Thriving despite Economic Hurdles.”J.sg,5 Dec.2024,.sg/en/trends-and-insights/research/apacs-middle-class-thriving-despite-economic-hurdles.5.IHH Healthcare.IHH Healthcare Malaysia Leads the Way in Value-Driven Outcomes with the Aim to Transition to Value-Based Healthcare.29 July 2024.6.National University Health System.“Value-Based Healthcare.”NUHS,www.nuhs.edu.sg/about-nuhs/value-based-healthcare.7.“NHA|Official Website Ayushman Bharat Digital Mission.”Abdm.gov.in,abdm.gov.in/.8.Oxford Economics.“The Future of the Middle Class in Emerging Markets.”Oxford Economics,16 Oct.2024, HealthTech Agency.”www.synapxe.sg,www.synapxe.sg/.10.The Mobile Economy Asia Pacific 2024.GSMA,2024, al.“Towards Conversational Diagnostic Artificial Intelligence.”Nature,2025,doi.org/10.1038/s41586025088667,https:/doi.org/10.1038/s41586025088667.12.United Nations.“ESCAP|Demographic Changes.”Www.population-Trends-Asiapacific.org,www.population-trends-asiapacific.org/data/escap.13.World Bank.“GDP per Capita(Current US$).”World Bank,2025,data.worldbank.org/indicator/NY.GDP.PCAP.CD|19About the authorsSAM SCIBETTA,Consultant,Consulting Services,IQVIASam is a Consultant in the APAC Consulting team based out of Singapore.He has 5 years of healthcare strategy experience focused on emerging markets in the Asia-Pacific.At IQVIA,Sam has delivered projects for global pharma,medical device,and hospitals across Asia-Pacific,as well as the U.S.,covering market access,growth strategy,and landscape opportunity assessments.Sam holds a Master of Business Administration from INSEAD(Singapore&France)and a Bachelor of Physics from Colorado College(USA).DEVARAJ SUBRAMANIAM,Principal,Consulting Services,IQVIADevaraj is a Principal and Malaysia Consulting Lead based out of Kuala Lumpur,Malaysia.He has over 15 years of experience leading engagements across Asia-Pacific covering operations transformation,public health strategy,portfolio and opportunity benchmarking,and commercial excellence for clients in the healthcare and life-sciences sector.About IQVIA Asia Pacific IQVIA(NYSE:IQV)is a leading global provider of clinical research services,commercial insights and healthcare intelligence to the life sciences and healthcare industries.IQVIAs portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and accelerate innovations.With approximately 88,000 employees in over 100 countries,IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.With regional headquarters in Singapore and offices in 15 countries,IQVIA Asia Pacific provides technology-enabled services and solutions to meet the growing and rapidly changing needs of clients,both local and multinational,operating in Asia Pacific.IQVIA is committed to advancing healthcare by offering evidence-based insights and deep domain expertise in thought leadership,with the aim of improving understanding and accelerating innovation within the healthcare ecosystem.To learn more,visit rights reserved.IQVIA is a registered trademark of IQVIA Inc.in the United States,the European Union,and various other countries.07.2025.APAC.BCS2025-1669-06JUNCONTACT US

2025-07-09 22页 5星级

Evaluate：2025全球医药前瞻性报告：动荡格局与中国崛起下的稳健增长（英文版）（31页）.pdf

Click here or press enter for the accessibility optimised versionWorld Preview2025Pharma Growth Stea.

2025-07-09 31页 5星级

世界卫生组织：2025虫媒病毒病临床管理指南：登革热、基孔肯雅热、寨卡病毒病与黄热病（英文版）（125页）.pdf

WHO guidelines for clinical management of arboviral diseases:dengue,chikungunya,Zika and yellow fev.

2025-07-08 125页 5星级

黑天鹅数据：美国健康产业的未来研究报告：2025+五大超级趋势（英文版）（27页）.pdf

5 mega-trends for 2025+THE FUTURE OF HEALTH AND WELLNESSOZEMPIC+26%SPIRULINA+32%ENHANCES BEAUTY+9%BL.

2025-07-08 27页 5星级

艾昆纬：2025患者等待获取创新疗法（W.A.I.T.）指标调查报告：2024年结果（英文版）（70页）.pdf

2025.All rights reserved.IQVIA is a registered trademark of IQVIA Inc.in the United States,the Euro.

2025-07-08 70页 5星级

世界卫生组织（WHO）：2025全球健康领域神经技术机遇与挑战全景分析报告（英文版）（32页）.pdf

Landscape analysis of the opportunities and challenges forneurotechnology in global healthLandscape .

2025-07-07 32页 5星级

Mandala Partners：2025澳大利亚医疗消费者自付费用降低策略研究报告（英文版）（35页）.pdf

Reducing out-of-pocket costs for Australian healthcare consumers MARCH 2025This document is intended.

2025-07-04 35页 5星级

美国健康信托基金：2025美国之痛：酒精、药物过量及自杀死亡流行趋势报告（英文版）（60页）.pdf

ISSUE REPORTMAY 2025Pain in the Nation:The Epidemics of Alcohol,Drug,and Suicide DeathsSPECIAL FEATU.

2025-07-04 60页 5星级

威科医疗&益普索：2025年未来医疗调查报告（英文版）（17页）.pdf

2025 Future Ready Healthcare Survey ReportGenerative AI:Balancing todays needs and tomorrows vision .

2025-07-04 17页 5星级

克林顿健康发展组织&ampATscale：2025残疾人辅助器具市场报告（英文版）（86页）.pdf

ASSISTIVE PRODUCTSMARKET REPORT 2025Insights into the demand landscape and supply-cost components fo.

2025-07-04 86页 5星级

英国标准协会：2025临界点：制药、医疗科技与医疗行业循环经济信任构建白皮书（英文版）（24页）.pdf

Pharmaceutical,MedTech,&Healthcare sectorsThe Tipping Point:Building trust in the circular economy 2.

2025-07-04 24页 5星级

西蒙顾和：2025中东欧国家医药市场定价与市场准入六大误区研究报告（英文版）（24页）.pdf

simon-Christian Schuler,Senior PartnerWiktor Miller,Senior ManagerSix P&MA myths about the pharmaceu.

2025-07-03 24页 5星级

世界心脏联盟（WHF）：2025年世界心脏报告：肥胖与心血管疾病（英文版）（35页）.pdf

DISEASEWORLD HEART REPORT 2025OBESITY&CARDIOVASCULARAUTHORS Francisco Lopez-Jimenez*,Mariachiara Di .

2025-07-03 35页 5星级

世界卫生组织&ampITU&ampWIPO：2025人工智能在传统医学中的应用：技术报告（英文版）（52页）.pdf

Mapping the application of artificial intelligence in traditional medicine1Mapping the application o.

2025-07-03 52页 5星级

莱坊国际：2025年英国医疗行业投资趋势与表现研究报告（英文版）（20页）.pdf

Healthcare Capital Markets capital flows back into the healthcare sector.HEALTHCARE CAPITAL MARKETS .

2025-07-03 20页 5星级

毕马威（KPMG）：2025生成式AI赋能护理行业转型研究报告（英文版）（22页）.pdf

2025 KPMG,an Australian partnership and a member firm of the KPMG global organisation of independent.

2025-07-02 22页 5星级